Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | June 21, 2023 | June 23, 2023 |
| Translate Bio, Inc.TBIO · Entity 135439 | Chief Medical Officer | March 09, 2021 | March 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date June 21, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2033-06-21 | Direct | 40,000 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.
Translate Bio, Inc.
Report date March 09, 2021 · Filed March 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82 · Expires 2031-03-09 | Direct | 70,000 |
Reported balance
After 2021-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-09 · Grant · Acquired 70,000 · Balance 70,000 F1: This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2023 Filed Jun 23, 2023 16:47 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001437749-23-018284 · rdgdoc.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 19:04 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001583648-22-000054 · wf-form4_165611185402944.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2023 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 17:19 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004558 · primarydocument.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2022 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 09, 2021 Filed Mar 9, 2021 20:24 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $23.82 | $0.00 |
DisclosureSEC source: 0001209191-21-019301 · doc4.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-09 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 16:44 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to buy) · Derivative | 40,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001562180-20-004686 · primarydocument.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on June 23, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:47 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001209191-20-016797 · doc4.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-03-02 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 16:21 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001562180-20-000622 · primarydocument.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 18:09 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-19-018945 · doc4.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:35 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-19-000570 · primarydocument.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:13 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001562180-18-002004 · primarydocument.xml · derivative · entry 1 Barbier Ann · CIK 0001737596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-04-25 F1 · derivative.exercise_date: The stock option will vest in four equal quarterly installments on each of June 30, 2018, September 30, 2018, December 31, 2018 and March 31, 2019, subject to the Reporting Person's continued service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.